Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Marketed as Egrifta, it was approved in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy
Research shows this peptide enhances collagen formation and improves the structural integrity of damaged connective tissues
Whether it's a unique dosage form, an allergen-free formulation, or a medication that is no longer commercially available, PCCA's diverse product offerings allow us to craft solutions that address individual patient needs effectively
* Shipping fee for any return caused by our fault will be paid by the company
10 single-dose 1.0 ml vials Item# 1165-011210 NDC# 69680-0112-10
To develop liver fibrosis, rats in Group 2, the TAA group, received IP injections of TAA (100 mg/kg b.wt), twice weekly for 6 weeks (Abd El-Rahman and Fayed, 2019)
